Glycans play a crucial role in many biological processes, from cell signaling and immune response to disease progression. However, accurately quantifying these complex carbohydrates has long been a challenge in biomedical research. That’s where CarboQuant comes in—our proprietary technology designed to provide absolute glycan quantification with unparalleled precision. By leveraging synthetic ¹³C-labeled N-glycans and mass spectrometry, CarboQuant enables researchers to uncover glycan biomarkers linked to diseases such as cancer, Alzheimer’s, and diabetes, driving forward innovation in diagnostics and therapeutics.
The Significance of Glycans in Disease Research
Glycans, complex carbohydrates present on the surfaces of cells and proteins, play pivotal roles in numerous biological processes, including cell signaling, immune response modulation, and protein stability. Alterations in glycan structures are often associated with various diseases, such as cancer, Alzheimer’s, and diabetes. Therefore, precise glycan analysis is essential for understanding disease mechanisms and developing effective diagnostics and therapeutics.
CarboQuant Technology: Revolutionizing Glycan Quantification
CarboQuant stands out as a patented technology developed by Asparia Glycomics, utilizing synthetic 13C-labeled N-glycans for absolute quantification by mass spectrometry. This approach ensures high precision in glycan measurement, which is crucial for identifying disease-specific glycan biomarkers. The technology’s robustness and accuracy have made it a valuable asset in biopharmaceutical research, particularly in quality control and biomarker discovery.
Applications of CarboQuant in Disease Research
Cancer Diagnostics and Prognostics
Aberrant glycosylation patterns are a hallmark of many cancers. CarboQuant enables the detailed profiling of these glycan alterations, facilitating the identification of potential biomarkers for early cancer detection and prognosis. By providing absolute quantification, researchers can distinguish subtle differences in glycan expression that may correlate with tumor progression or response to therapy.
Alzheimer’s Disease Research
In neurodegenerative diseases like Alzheimer’s, glycosylation changes can affect protein aggregation and neuronal function. Utilizing CarboQuant, scientists can accurately measure these glycan modifications, shedding light on disease pathways and identifying novel therapeutic targets. This precise quantification is essential for developing strategies to mitigate glycan-related pathogenic mechanisms in Alzheimer’s disease.
Diabetes and Metabolic Disorders
Glycans play a significant role in insulin activity and glucose metabolism. Alterations in glycan structures can influence insulin resistance and the development of diabetes. CarboQuant might facilitate the monitoring of these glycan changes, aiding in the understanding of disease progression and the development of glycan-targeted therapies.
Integration with Industry-Standard Platforms
Asparia Glycomics has ensured that CarboQuant technology is compatible with widely used analytical platforms for Mass Spectrometry and MALDI. This compatibility allows for seamless integration into existing workflows, enabling researchers to adopt CarboQuant without the need for extensive modifications to their current systems. The result is a streamlined process for glycan analysis, enhancing efficiency and accuracy in research applications.
Custom Glycan Synthesis Services
Recognizing that research needs can vary, and some N-glycan standards are not always commercially available, Asparia Glycomics offers custom glycan synthesis services, including SIL (Stable Isotope Labeled)-standards. This flexibility allows scientists to obtain specific glycan structures tailored to their research objectives, whether for developing new therapeutics or exploring unique disease mechanisms. The ability to customize glycan standards ensures that researchers have the precise tools necessary for their specific applications.
Global Impact and Collaborations
Operating on an international scale, Asparia Glycomics collaborates with pharmaceutical companies, biotech firms, and academic institutions. Their technologies and services have been instrumental in advancing glycomics research worldwide, contributing to significant progress in understanding and treating complex diseases. These collaborations have facilitated the translation of glycan research into clinical applications, ultimately benefiting patient care and therapeutic development.
Future Directions
Asparia Glycomics is committed to expanding its technological capabilities and service offerings. Plans include a wider implementation of the CarboQuant technology and the use of the standards for a better exploration of glycan-related biomarkers and in a broader range of diseases. By staying at the cutting edge of glycoscience, Asparia Glycomics aims to provide researchers and scientists with the necessary tools to drive innovations in diagnostics and therapeutics.
Conclusion
The CarboQuant technology represents a significant advancement in the field of glycan analysis. Its precise quantification capabilities are invaluable for disease research, offering insights into glycan-related mechanisms across various pathologies. As the scientific community continues to uncover the complexities of glycosylation in health and disease, tools like CarboQuant will be essential in translating this knowledge into tangible medical advancements.
References
Aizpurua-Olaizola, O., Sastre Toraño, J., Falcon-Perez, J. M., Williams, C., Reichardt, N., & Boons, G.-J. . (2018). Mass spectrometry for glycan biomarker discovery. TrAC Trends in Analytical Chemistry, 100, 7–14. https://doi.org/10.1016/j.trac.2017.12.015
Etxebarria, J., & Reichardt, N.-C. (2016). Methods for the absolute quantification of N-glycan biomarkers. Biochimica et Biophysica Acta (BBA) – General Subjects, 1860(8), 1676–1687. https://doi.org/10.1016/j.bbagen.2016.03.003
Echeverria, B., Etxebarria, J., Ruiz, N., Hernandez, Á., Calvo, J., Haberger, M., Reusch, D., & Reichardt, N.-C. (2015). Chemo-Enzymatic Synthesis of 13C Labeled Complex N-Glycans As Internal Standards for the Absolute Glycan Quantification by Mass Spectrometry. Analytical Chemistry, 87(22), 11460–11467. https://doi.org/10.1021/acs.analchem.5b03135